Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK

被引：0
|
作者：
Alex Diamantopoulos
A. Finckh
T. Huizinga
D. K. Sungher
L. Sawyer
D. Neto
F. Dejonckheere
机构：
[1] Symmetron Limited,Rheumatology
[2] Kinetic Centre,Rheumatology
[3] University Hospitals of Geneva,undefined
[4] Leiden University Medical Center,undefined
[5] F. Hoffmann-La Roche,undefined
来源：
PharmacoEconomics | 2014年 / 32卷
关键词：
Palliative Care; Juvenile Idiopathic Arthritis; Tocilizumab; Visual Analogue Scale Pain; Health Assessment Questionnaire;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：775 / 787
页数：12
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF TOCILIZUMAB COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF MODERATE/SEVERE RHEUMATOID ARTHRITIS (RA) IN ITALY
    Diamantopoulos, A.
    Wintfeld, N.
    Giuliani, G.
    VALUE IN HEALTH, 2009, 12 (07) : A443 - A443
  • [22] THE COST-EFFECTIVENESS OF ALTERNATIVE TREATMENT SEQUENCES IN RHEUMATOID ARTHRITIS
    Trueman, D.
    Bird, A.
    Mumby-Croft, J.
    VALUE IN HEALTH, 2014, 17 (03) : A48 - A48
  • [23] Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment
    Drosos, Alexandros A.
    Pelechas, Eleftherios
    Kaltsonoudis, Evripidis
    Voulgari, Paraskevi V.
    CURRENT RHEUMATOLOGY REPORTS, 2020, 22 (08)
  • [24] Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment
    Alexandros A. Drosos
    Eleftherios Pelechas
    Evripidis Kaltsonoudis
    Paraskevi V. Voulgari
    Current Rheumatology Reports, 2020, 22
  • [25] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SUBCUTANEOUS AS FIRST LINE BIOLOGIC MONOTHERAPY FOR RHEUMATOID ARTHRITIS MANAGEMENT IN GREECE
    Athanasakis, K.
    Tarantilis, F.
    Skroumpelos, A.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2015, 18 (07) : A671 - A671
  • [26] Cost-effectiveness analysis of rituximab for rheumatoid arthritis in Taiwan
    Lou, S. F.
    Chen, D. Y.
    Cheng, T. T.
    Huang, C. M.
    Lin, H. Y.
    Su, C. C.
    Tsai, W. C.
    Tseng, J. C.
    Wei, C. C.
    Yang, L.
    Hazard, S.
    Chang, D. M.
    VALUE IN HEALTH, 2008, 11 (03) : A257 - A258
  • [27] COMBINATION DMARDS FOR RHEUMATOID ARTHRITIS: A COST-EFFECTIVENESS ANALYSIS
    Tosh, Jonathan
    Wailoo, Allan
    RHEUMATOLOGY, 2009, 48 : I68 - I69
  • [28] A cost-effectiveness analysis of biological treatments for rheumatoid arthritis
    Chiou, CF
    Wanke, L
    Yu, E
    Ofman, J
    VALUE IN HEALTH, 2004, 7 (03) : 223 - 223
  • [29] Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain
    F. Navarro
    J. M. Martinez-Sesmero
    A. Balsa
    C. Peral
    M. Montoro
    M. Valderrama
    S. Gómez
    F. de Andrés-Nogales
    M. A. Casado
    Itziar Oyagüez
    Clinical Rheumatology, 2020, 39 : 2919 - 2930
  • [30] Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain
    Navarro, F.
    Martinez-Sesmero, J. M.
    Balsa, A.
    Peral, C.
    Montoro, M.
    Valderrama, M.
    Gomez, S.
    De Andres-Nogales, F.
    Casado, M. A.
    Oyaguez, Itziar
    CLINICAL RHEUMATOLOGY, 2020, 39 (10) : 2919 - 2930
12345